SANTA ANA, California – (BUSINESS WIRE) – FUJIFILM Irvine Scientific, Inc. celebrates its 50th anniversary with innovative products and services for cell culture media. Since its inception, the company has made a name for itself as an innovator and market leader in providing cell culture solutions to the life science and medical markets.
Since its inception in the 1970s as a supplier of fetal bovine serum, the company has consistently provided groundbreaking cell culture solutions. In the 1980s, it revolutionized embryo culture using commercially available media for in vitro fertilization clinics (IVF) worldwide. In the 1990s, the company brought chemically defined media to biotherapeutic manufacturers. Most recently, FUJIFILM Irvine Scientific launched products that better support cell culture-based vaccine production as well as advanced cell and gene therapy applications. Since it was acquired by FUJIFILM Corporation, the company has expanded its global reach and production capacity at a faster rate. This expansion enables the company to meet the growing demands of customers in the life science and medicine sectors.
“We have reflected on our groundbreaking history and many contributions over the past five decades. Our 50th year coincided with unprecedented challenges from the COVID-19 pandemic. “Said Yutaka Yamaguchi, CEO and Chairman of the Board of FUJIFILM Irvine Scientific. “We are grateful for the dedication and commitment of our employees to meet our standards for delivering the highest quality products and services under these difficult conditions. We are also humble of the extraordinary community efforts we are putting into the fight against the virus, and are honored that our customers trust FUJIFILM Irvine Scientific to provide the critical cell culture media used in the manufacture of life-saving therapies and vaccines, as well as medical support Applications are required. We are inspired to continue our mission of improving health through innovation, partnership and service for the next 50 years. ”
Tim Mullane, President and COO of FUJIFILM Irvine Scientific, commented, “Our history in medical and life science applications includes many innovations and improvements in cell culture. These advances have enabled our customers to get better and more consistent results from their cell culture, which in turn has resulted in tremendous company growth. Due to the pandemic, we had to accelerate plans to expand production capacity. We have doubled our capacity in California and expect production at our Dutch facility before the end of 2021. During this strong demand for COVID-19 therapies and vaccines, our entire organization is motivated to implement programs such as collaborations with the US government and others to combat it to support the pandemic. ”